Trial results

Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

NCT06449235 on ClinicalTrials.gov · last registry update 2024-07-16

An unusually large phase 4: 938 participants, more than double the 72 typical for the stage. Its estimated completion date, April 2025, has passed with no update to the record. Primary outcome, as filed: Glycemic Control as Measured by HbA1c Levels. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here.

Status

UNKNOWN

Phase

P4

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders

Sponsor type

Other

Enrollment

938

Started

2024-09

Primary completion

2025-04 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Glycemic Control as Measured by HbA1c Levels

Conditions studied

Type2diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.